Intellia Therapeutics (NTLA) Shares Gap Down to $22.71

Intellia Therapeutics Inc (NASDAQ:NTLA) shares gapped down before the market opened on Tuesday . The stock had previously closed at $25.40, but opened at $22.71. Intellia Therapeutics shares last traded at $20.03, with a volume of 3188700 shares trading hands.

A number of research analysts have recently commented on NTLA shares. Oppenheimer reaffirmed a “hold” rating on shares of Intellia Therapeutics in a research note on Tuesday, December 12th. Barclays reaffirmed a “buy” rating on shares of Intellia Therapeutics in a research note on Sunday, November 5th. Credit Suisse Group upped their target price on Intellia Therapeutics from $24.00 to $28.00 and gave the company an “outperform” rating in a research note on Friday, November 3rd. Jefferies Group reaffirmed a “buy” rating and set a $36.00 target price on shares of Intellia Therapeutics in a research note on Tuesday, October 3rd. Finally, Zacks Investment Research raised Intellia Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, October 4th. One analyst has rated the stock with a sell rating, five have given a hold rating and four have given a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $30.17.

The firm has a market cap of $853.48 and a P/E ratio of -13.01.

Intellia Therapeutics (NASDAQ:NTLA) last announced its quarterly earnings data on Tuesday, October 31st. The company reported ($0.44) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.50) by $0.06. Intellia Therapeutics had a negative return on equity of 28.01% and a negative net margin of 215.92%. The company had revenue of $7.30 million for the quarter, compared to analysts’ expectations of $5.83 million. During the same quarter in the prior year, the firm earned ($0.22) earnings per share. Intellia Therapeutics’s revenue was up 49.0% compared to the same quarter last year. equities analysts predict that Intellia Therapeutics Inc will post -1.68 earnings per share for the current fiscal year.

In related news, CEO Nessan Bermingham sold 111,500 shares of the stock in a transaction that occurred on Wednesday, December 6th. The stock was sold at an average price of $20.34, for a total value of $2,267,910.00. Following the transaction, the chief executive officer now owns 696,000 shares of the company’s stock, valued at $14,156,640. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Institutes For Biomed Novartis sold 1,523,000 shares of the stock in a transaction on Tuesday, December 12th. The shares were sold at an average price of $18.30, for a total value of $27,870,900.00. The disclosure for this sale can be found here. In the last three months, insiders sold 1,971,283 shares of company stock worth $37,137,161. 12.80% of the stock is owned by insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in NTLA. GMT Capital Corp bought a new stake in Intellia Therapeutics during the 3rd quarter valued at $8,214,000. Ark Investment Management LLC boosted its position in Intellia Therapeutics by 118.9% during the 2nd quarter. Ark Investment Management LLC now owns 174,810 shares of the company’s stock valued at $2,797,000 after acquiring an additional 94,960 shares in the last quarter. Vanguard Group Inc. boosted its position in Intellia Therapeutics by 10.2% during the 2nd quarter. Vanguard Group Inc. now owns 997,288 shares of the company’s stock valued at $15,957,000 after acquiring an additional 92,580 shares in the last quarter. OxFORD Asset Management LLP bought a new stake in Intellia Therapeutics during the 2nd quarter valued at $1,132,000. Finally, GSA Capital Partners LLP bought a new stake in Intellia Therapeutics during the 2nd quarter valued at $907,000. 48.95% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: “Intellia Therapeutics (NTLA) Shares Gap Down to $22.71” was published by Community Financial News and is owned by of Community Financial News. If you are reading this story on another site, it was illegally copied and republished in violation of U.S. & international trademark and copyright legislation. The correct version of this story can be viewed at https://www.com-unik.info/2018/01/11/intellia-therapeutics-ntla-shares-gap-down-to-22-71.html.

About Intellia Therapeutics

Intellia Therapeutics, Inc is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene.

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit